Genomic–transcriptomic evolution in lung cancer and metastasis
Cancer Research UK · London Cancer · +64 more institutions
Abstract
Abstract Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion and resistance to therapy 1 . Here, using paired whole-exome and RNA sequencing data, we investigate intratumour transcriptomic diversity in 354 non-small cell lung cancer tumours from 347 out of the first 421 patients prospectively recruited into the TRACERx study 2,3 . Analyses of 947 tumour regions, representing both primary and metastatic disease, alongside 96 tumour-adjacent normal tissue samples implicate the transcriptome as a major source of phenotypic variation. Gene expression levels and ITH relate to patterns of positive and negative selection during tumour evolution. We observe frequent copy…
Citation impact
- FWCI
- 47.03
- Percentile
- 100%
- References
- 115
Authors
297- CMCarlos Martínez‐RuizCorresponding
Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
- JRJames R. Black
Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
- CPClare Puttick
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
- MSMark S. Hill
The Francis Crick Institute, London Cancer, University College London
- JDJonas Demeulemeester
The Francis Crick Institute, VIB-KU Leuven Center for Cancer Biology, Genomics (United Kingdom)
Topics & keywords
- Transcriptome
- Lung cancer
- Metastasis
- Biology
- Computational biology
- Genome
- Cancer
- Genetics
- Good health and well-being
Funding
- AAAmerican Association for Cancer Research
- BCBreast Cancer Research Foundation
- LFLUNGevity Foundation
- CPCancer Prevention and Research Institute of TexasAward: RR210006
- IAInternational Association for the Study of Lung Cancer
- EIEntertainment Industry Foundation
- AUAarhus Universitet
- WTWellcome TrustAwards: CC2041, 218274/Z/19/Z, 211179/Z/18/Z
- FCFrancis Crick InstituteAward: CC2041
- MFMark Foundation For Cancer ResearchAwards: Grant 21-029-ASP, 21-029-ASP
- CRCancer Research UKAwards: C7893/A26233, C11496/A30025, C416/A21999, A17786, CC2008, C416/, ID16584, C444/A15953, C11496/A17786, CC2041, C69256/A30194
- NINational Institute for Health and Care ResearchAward: C444/A15953
- RSRoyal SocietyAwards: RSRP\R\210001, 211179/Z/18/Z, 211179, RP/EA/180007
- FFFoulkes Foundation
- UCUniversity College LondonAward: UCL/12/0279
- ECEuropean CommissionAwards: 703594, FP7-PEOPLE-2013, 703228, 607722, 835297
- RTRosetrees TrustAwards: ID16584, A2437
- AUAarhus Universitets ForskningsfondAward: AUFF-E-2018-7-14
- FWFonds Wetenschappelijk OnderzoekAward: 12J6916N
- LLundbeckfondenAward: R272-2017-4040
- NNNovo Nordisk
- NNNovo Nordisk FondenAwards: 16584, ID 16584, ID16584, NNF21OC0071483
- VRVlaamse regering
- HLH. Lundbeck A/S
- SUStand Up To CancerAwards: SU2C-AACR-DT23-17, AACR-DT23-17
- MRMedical Research CouncilAwards: MR/P014712/1, MR/V033077/1, CC2008, MR/W025051/1, MR/V033077/1, MR/P014712/1, MR/L016311/1, MR/L016311/1, CC2041
- JSJapan Society for the Promotion of ScienceAward: 2018-7
- FPFP7 People: Marie-Curie ActionsAwards: 607722, FP7-PEOPLE-2013